Intelligent Bio Solutions

Intelligent Bio Solutions Liabilities

The The Liabilities of Intelligent Bio Solutions (INBS) as of Oct 26, 2026 is 6.65 M USD. In the previous year, The Liabilities was 5.44 M USD — a change of 22.35% (higher).

Liabilities

6.65 MUSD

YoY

22.35%

Last updated:

In 2026, Intelligent Bio Solutions's total liabilities amounted to 6.65 M USD, a 22.35% difference from the 5.44 M USD total liabilities in the previous year.

The Intelligent Bio Solutions Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2019
6.31 M USD
Jan 1, 2020
7.69 M USD
Jan 1, 2021
6.85 M USD
Jan 1, 2022
5.81 M USD
Jan 1, 2023
6.67 M USD
Jan 1, 2024
5.60 M USD
Jan 1, 2025
5.44 M USD
Jan 1, 2026
6.65 M USD
The Intelligent Bio Solutions Liabilities history
YEARLiabilitiesYoY
6.65 MUSD+22.35%
5.44 MUSD-2.85%
5.60 MUSD-16.08%
6.67 MUSD+14.83%
5.81 MUSD-15.27%
6.85 MUSD-10.89%
7.69 MUSD+21.97%
6.31 MUSD+13.41%
5.56 MUSD-15.50%
6.58 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Intelligent Bio Solutions Stock analysis

What does Intelligent Bio Solutions do? Intelligent Bio Solutions, Inc. generates revenue through its Commercially available Intelligent Fingerprinting Products (IFPG) segment, which includes a portable drug screening system analyzing fingerprint sweat via a one-time cartridge and handheld reader. The company also develops diagnostic tests under the Development Stage Saliva Glucose Biosensor Platform (SGBP), targeting diabetic patients with a non-invasive saliva glucose biosensor (SGB) intended to replace finger-prick blood monitoring. Its biosensor platform supports multiple biological analyte detection for point-of-care diagnostic tests (POCT) in clinical chemistry, immunology, tumor markers, allergens, and endocrinology. The firm serves primary health practitioners and patients seeking non-invasive monitoring solutions. The company's product portfolio features the IFPG segment's portable drug screening system, which is sold to healthcare providers and law enforcement agencies for rapid drug testing. The SGBP segment focuses on developing the Saliva Glucose Biosensor (SGB), a point-of-care diagnostic test expected to address the needs of diabetic patients requiring frequent glucose monitoring without invasive procedures. The biosensor platform enables detection of multiple analytes, expanding the company's offerings in clinical chemistry and related diagnostic fields. Intelligent Bio Solutions, Inc. targets primary health practitioners and patients as key segments for its non-invasive diagnostic solutions. The IFPG segment's portable drug screening system is designed for use in clinical and law enforcement settings, while the SGBP segment's Saliva Glucose Biosensor aims to provide a convenient alternative to traditional blood glucose monitoring for diabetic patients. The company's development stage products focus on replacing invasive methods with real-time, non-invasive monitoring technologies. Intelligent Bio Solutions is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Intelligent Bio Solutions's Liabilities

Intelligent Bio Solutions's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Intelligent Bio Solutions's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Intelligent Bio Solutions's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Intelligent Bio Solutions's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Intelligent Bio Solutions’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Intelligent Bio Solutions stock

The Liabilities of Intelligent Bio Solutions is 6.65 M USD in 2026.

The Liabilities of Intelligent Bio Solutions changed from 5.44 M USD to 6.65 M USD, representing a 22.35% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Intelligent Bio Solutions since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Intelligent Bio Solutions historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Intelligent Bio Solutions

All Key Metrics — Intelligent Bio Solutions